Redx Pharma inks $880m deal with Jazz Pharma; will bank $10m immediatelyProactive Investors • 02/07/24
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor ProgramPRNewsWire • 02/07/24
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024InvestorPlace • 01/31/24
Jazz Pharmaceuticals targets positive momentum in 2024, receives Outperform ratingProactive Investors • 01/03/24
Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress DisorderPRNewsWire • 12/21/23
Jazz Pharmaceuticals' Zanidatamab Promises Growth Amidst Market UndervaluationSeeking Alpha • 12/21/23
Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferencePRNewsWire • 12/20/23
Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast CancerPRNewsWire • 12/08/23
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual MeetingPRNewsWire • 12/01/23
Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology MeetingsPRNewsWire • 11/30/23
Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological DisordersBusiness Wire • 11/14/23
Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 11/09/23
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial GuidancePRNewsWire • 11/08/23
Unlocking Q3 Potential of Jazz (JAZZ): Exploring Wall Street Estimates for Key MetricsZacks Investment Research • 11/07/23